NFDI4DS | UHH-SEMS - Publication Details

Jessica Boros

ORCID: 0000-0002-4090-4253

Publications

Citations

Views

---

Saved

---

About

Contact & Profiles

A5063452473

Research Areas

Ovarian cancer diagnosis and treatment
PARP inhibition in cancer therapy
Virus-based gene therapy research
CRISPR and Genetic Engineering
RNA modifications and cancer
Cancer Mechanisms and Therapy
Cancer Genomics and Diagnostics
Fibroblast Growth Factor Research
Connexins and lens biology
Ferroptosis and cancer prognosis
Aldose Reductase and Taurine
Cancer Immunotherapy and Biomarkers
Urological Disorders and Treatments
Molecular Biology Techniques and Applications
Endometriosis Research and Treatment
Cancer-related Molecular Pathways
Cytomegalovirus and herpesvirus research
interferon and immune responses
Chromatin Remodeling and Cancer
Animal Virus Infections Studies
Diet, Metabolism, and Disease
Circadian rhythm and melatonin
Effects of Environmental Stressors on Livestock
Prenatal Screening and Diagnostics
FOXO transcription factor regulation

Westmead Institute for Medical Research
2020-2024

Westmead Hospital
2020-2024

The University of Sydney
2007-2024

Robert Bosch (Australia)
2006-2015

Vision Cooperative Research Centre
2009

CCNE1 and survival of patients with tubo‐ovarian high‐grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study

OPENALEX - Publications

Eunyoung Kang Ashley Weir Nicola S. Meagher Kyo Farrington Gregg Nelson and 95 more

Abstract Background Cyclin E1 (CCNE1) is a potential predictive marker and therapeutic target in tubo‐ovarian high‐grade serous carcinoma (HGSC). Smaller studies have revealed unfavorable associations for CCNE1 amplification overexpression with survival, but to date no large‐scale, histotype‐specific validation has been performed. The hypothesis was that high‐level of overexpression, as well combination the two, are linked shorter overall survival HGSC. Methods Within Ovarian Tumor Tissue...

10.1002/cncr.34582 article EN cc-by Cancer 2022-12-26

Concurrent RB1 Loss and BRCA-Deficiency Predicts Enhanced Immunological Response and Long-Term Survival in Tubo-Ovarian High-Grade Serous Carcinoma

OPENALEX - Publications

Flurina A.M. Saner Kazuaki Takahashi Timothy Budden Ahwan Pandey Dinuka Ariyaratne and 92 more

Abstract Purpose: The purpose of this study was to evaluate RB1 expression and survival across ovarian carcinoma histotypes how co-occurrence BRCA1 or BRCA2 (BRCA) alterations loss influences in tubo-ovarian high-grade serous (HGSC). Experimental Design: protein classified by immunohistochemistry carcinomas 7,436 patients from the Ovarian Tumor Tissue Analysis consortium. We examined germline BRCA status a subset 1,134 HGSC, related genotype overall (OS), tumor-infiltrating CD8+ lymphocytes,...

10.1158/1078-0432.ccr-23-3552 article EN cc-by Clinical Cancer Research 2024-06-05

Molecular pathology of ovarian cancer in the INOVATe program (Individualised Ovarian Cancer Treatment Through Integration of Genomic Pathology into Multidisciplinary Care)

OPENALEX - Publications

Rosemary L. Balleine Lyndal Anderson Spinder Samra Raghwa Sharma King Tan and 9 more

10.1016/j.pathol.2024.12.021 article EN Pathology 2025-01-23

p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study

OPENALEX - Publications

Martin Köbel Eunyoung Kang Ashley Weir Peter Rambau Cheng‐Han Lee and 95 more

Abstract Our objective was to test whether p53 expression status is associated with survival for women diagnosed the most common ovarian carcinoma histotypes (high‐grade serous [HGSC], endometrioid [EC], and clear cell [CCC]) using a large multi‐institutional cohort from Ovarian Tumor Tissue Analysis (OTTA) consortium. assessed on 6,678 cases represented tissue microarrays 25 participating OTTA study sites previously validated immunohistochemical (IHC) assay as surrogate presence functional...

10.1002/cjp2.311 article EN cc-by The Journal of Pathology Clinical Research 2023-03-22

Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8+ TIL infiltration, and provides no independent prognostic value in endometriosis‐associated ovarian carcinomas

OPENALEX - Publications

Karolin Heinze Tayyebeh M. Nazeran Sandra Lee Pauline Krämer Evan S. Cairns and 77 more

Abstract ARID1A (BAF250a) is a component of the SWI/SNF chromatin modifying complex, plays an important tumour suppressor role, and considered prognostic in several malignancies. However, ovarian carcinomas there are contradictory reports on its relationship to outcome, immune response, correlation with clinicopathological features. We assembled series 1623 endometriosis‐associated carcinomas, including 1078 endometrioid (ENOC) 545 clear cell (CCOC) through combining resources Ovarian Tumor...

10.1002/path.5849 article EN The Journal of Pathology 2021-12-13

Negative regulation of TGFβ-induced lens epithelial to mesenchymal transition (EMT) by RTK antagonists

OPENALEX - Publications

Guannan Zhao Magdalena C. Wojciechowski Seonah Jee Jessica Boros John W. McAvoy and 1 more

10.1016/j.exer.2015.01.001 article EN Experimental Eye Research 2015-01-07

Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes

OPENALEX - Publications

Nicola S. Meagher Kylie L. Gorringe Matthew J. Wakefield Adelyn Bolithon Chi Nam Ignatius Pang and 95 more

Abstract Purpose: Advanced-stage mucinous ovarian carcinoma (MOC) has poor chemotherapy response and prognosis lacks biomarkers to aid stage I adjuvant treatment. Differentiating primary MOC from gastrointestinal (GI) metastases the ovary is also challenging due phenotypic similarities. Clinicopathologic gene-expression data were analyzed identify prognostic diagnostic features. Experimental Design: Discovery analyses selected 19 genes with prognostic/diagnostic potential. Validation was...

10.1158/1078-0432.ccr-22-1206 article EN cc-by Clinical Cancer Research 2022-10-07

Sef is a negative regulator of fiber cell differentiation in the ocular lens

OPENALEX - Publications

Peter Newitt Jessica Boros Bhavani P. Madakashira Michael L. Robinson Lixing W. Reneker and 2 more

10.1016/j.diff.2010.05.005 article EN Differentiation 2010-06-10

MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma

OPENALEX - Publications

Eun Young Kang Joshua Millstein Gordana Popović Nicola S. Meagher Adelyn Bolithon and 95 more

10.1007/s00428-021-03232-0 article EN Virchows Archiv 2021-11-15

The fate of dividing cells during lens morphogenesis, differentiation and growth

OPENALEX - Publications

Georgios Kallifatidis Jessica Boros Eun Hye H. Shin John W. McAvoy Frank J. Lovicu

10.1016/j.exer.2011.03.012 article EN Experimental Eye Research 2011-04-11

Immunological and molecular features of the tumor microenvironment of long-term survivors of ovarian cancer

OPENALEX - Publications

Brad H. Nelson Phineas T. Hamilton Minh Tung Phung Katy Milne Bronwyn Harris and 73 more

BACKGROUND. Despite an overall poor prognosis, about 15% of patients with advanced-stage tubo-ovarian high-grade serous carcinoma (HGSC) survive ten or more years after standard treatment. METHODS. We evaluated the tumor microenvironment this exceptional, understudied group using a large international cohort enriched for long-term survivors (LTS; 10+ years; n = 374) compared to medium-term (MTS; 5–7.99 433) and short-term (STS; 2–4.99 416). Primary samples were immunostained scored...

10.1172/jci179501 article EN cc-by Journal of Clinical Investigation 2024-10-29

Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study

OPENALEX - Publications

Ashley Weir Eunyoung Kang Nicola S. Meagher Gregg Nelson Prafull Ghatage and 95 more

Abstract Background Recently, we showed a >60% difference in 5-year survival for patients with tubo-ovarian high-grade serous carcinoma (HGSC) when stratified by 101-gene mRNA expression prognostic signature. Given the varied patient outcomes, this study aimed to translate markers into protein assays immunohistochemistry and validate their association HGSC. Methods Two genes, FOXJ1 GMNN , were selected based on high-quality antibodies, correlation variation immunohistochemical scores...

10.1038/s41416-022-02014-y article EN cc-by British Journal of Cancer 2022-11-02

Figure 1 from Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma

OPENALEX - Publications

Flurina A.M. Saner Kazuaki Takahashi Timothy Budden Ahwan Pandey Dinuka Ariyaratne and 92 more

Expression of RB1 and survival associations across ovarian cancer histotypes. A, Representative images IHC detection expression in carcinoma tissues, showing examples the three most common patterns: retained, lost, subclonal loss. B, Proportion patients with loss or retention protein tumor samples by χ2P value reported for difference proportions all CCOC, clear cell cancer; LGSC,...

10.1158/1078-0432.26711139.v1 preprint EN cc-by 2024-08-15

Supplementary Figure S10 from Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma

OPENALEX - Publications

Flurina A.M. Saner Kazuaki Takahashi Timothy Budden Ahwan Pandey Dinuka Ariyaratne and 92 more

Supplementary Figure S10. Immune cell subsets inferred from gene expression data by combined homologous recombination deficiency and RB1 status.

10.1158/1078-0432.26711118 preprint EN cc-by 2024-08-15

Supplementary Figure S5 from Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma

OPENALEX - Publications

Flurina A.M. Saner Kazuaki Takahashi Timothy Budden Ahwan Pandey Dinuka Ariyaratne and 92 more

Supplementary Figure S5. Cell proliferation and cell cycle distribution of HGSC lines with RB1 knockout.

10.1158/1078-0432.26711097 preprint EN 2024-08-15

Data from Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma

OPENALEX - Publications

Flurina A.M. Saner Kazuaki Takahashi Timothy Budden Ahwan Pandey Dinuka Ariyaratne and 92 more

<div>AbstractPurpose:The purpose of this study was to evaluate RB1 expression and survival across ovarian carcinoma histotypes how co-occurrence BRCA1 or BRCA2 (BRCA) alterations loss influences in tubo-ovarian high-grade serous (HGSC).Experimental Design:RB1 protein classified by immunohistochemistry carcinomas 7,436 patients from the Ovarian Tumor Tissue Analysis consortium. We examined germline...

10.1158/1078-0432.c.7403499.v1 preprint EN 2024-08-15

Supplementary Figure S2 from Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma

OPENALEX - Publications

Flurina A.M. Saner Kazuaki Takahashi Timothy Budden Ahwan Pandey Dinuka Ariyaratne and 92 more

Supplementary Figure S2. Representative immunohistochemical RB1 staining patterns.

10.1158/1078-0432.26711109.v1 preprint EN cc-by 2024-08-15

Supplementary Figure S10 from Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma

OPENALEX - Publications

Flurina A.M. Saner Kazuaki Takahashi Timothy Budden Ahwan Pandey Dinuka Ariyaratne and 92 more

Supplementary Figure S10. Immune cell subsets inferred from gene expression data by combined homologous recombination deficiency and RB1 status.

10.1158/1078-0432.26711118.v1 preprint EN cc-by 2024-08-15

Supplementary Figure S5 from Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma

OPENALEX - Publications

Flurina A.M. Saner Kazuaki Takahashi Timothy Budden Ahwan Pandey Dinuka Ariyaratne and 92 more

Supplementary Figure S5. Cell proliferation and cell cycle distribution of HGSC lines with RB1 knockout.

10.1158/1078-0432.26711097.v1 preprint EN cc-by 2024-08-15

Figure 2 from Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma

OPENALEX - Publications

Flurina A.M. Saner Kazuaki Takahashi Timothy Budden Ahwan Pandey Dinuka Ariyaratne and 92 more

Sensitivity to therapeutic agents in BRCA1-altered cell lines with RB1 knockout. A,RB1 was knocked out using CRISPR/Cas9 three patient-derived Australian Ovarian Cancer Study (AOCS) HGSC either wild-type or altered BRCA1 (BRCA1 var) background. Representative Western Blots show protein levels of RB1 and phosphorylated (pRB1) compared GAPDH loading control single-cell...

10.1158/1078-0432.26711136 preprint EN cc-by 2024-08-15

Supplementary Figure S6 from Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma

OPENALEX - Publications

Flurina A.M. Saner Kazuaki Takahashi Timothy Budden Ahwan Pandey Dinuka Ariyaratne and 92 more

Supplementary Figure S6. Mutational signatures in homologous recombination deficiency and RB1 subgroups.

10.1158/1078-0432.26711094 preprint EN cc-by 2024-08-15

Figure 3 from Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma

OPENALEX - Publications

Flurina A.M. Saner Kazuaki Takahashi Timothy Budden Ahwan Pandey Dinuka Ariyaratne and 92 more

Genomic landscape of high-grade serous ovarian tumors with co-occurring BRCA and RB1 alterations. A, Pathogenic germline somatic alterations in HR DNA repair genes detected by whole-genome sequencing methylation analysis 126 primary HGSC samples (<a href="#bib27" target="_blank">27</a>) are shown, as well immune CCNE1. Samples grouped status. Bars at the top indicate number each listed gene per...

10.1158/1078-0432.26711133 preprint EN cc-by 2024-08-15

Coming Soon ...